Sign up for free newsletter



Kurma Partners invests in OxThera

Kurma Partners’s Biofund II, the first venture capital fund dedicated to financing innovation in the rare diseases space, has made its maiden EUR7.5 million investment in Oxthera, a Stockholm-based biopharmaceutical company.

OxThera is currently conducting a placebo-controlled clinical trial with Oxabact in patients with primary hyperoxaluria at seven clinical sites in three countries.

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death.
Rémi Droller, managing partner of Kurma Partners, who joins the board of directors of OxThera, says: “This first investment of Kurma Biofund II, is fully consistent with our investment strategy to support business innovation for Life Sciences in Europe, in a context where the development of new treatments and diagnostic tools for rare diseases is increasingly sought-after by industrialists seeking therapeutic innovation.”

Subscribe to free daily newsletter
Global Head of Macro Risk - International Asset Manager

Sat, 28 Nov 2015 00:00:00 GMT

S/VP Enterprise Risk - Buy Side Firm | Singapore

Sat, 28 Nov 2015 00:00:00 GMT

Compliance Officer | Private Bank

Sat, 28 Nov 2015 00:00:00 GMT

59 min 15 sec from now - Hong Kong
59 min 15 sec from now - Boston
59 min 15 sec from now - London
2 days 59 min from now - London
other gfm publications